Use of Monoclonal Antibodies against COVID-19 – Xevudy (Sotrovimab) Available in Germany
Sotrovimab (trade name Xevudy), an additional COVID-19 treatment option, became available for use in Germany at the end of January 2022. It is a SARS-CoV-2 neutralising monoclonal antibody offered by the company GlaxoSmithKline (GSK) in Germany. Xevudy has been authorised in the EU since December 2021.
Xevudy is a human monoclonal antibody that binds to the receptor-binding domain of the SARS-CoV-2 spike protein. The European Commission approved Xevudy on 17 December 2021 for the treatment of COVID-19 in adults and adolescents aged 12 years and older who do not require supplemental oxygen and are at increased risk of severe disease progression.
Efficacy of Xevudy (sotrovimab) against viral variants
While Xevudy’s neutralising activity against the Delta variant is unrestricted, data currently indicates that neutralisation against the Omicron variant, although reduced by a factor of 3, is still retained. This is confirmed by the latest study results published by VIR Biotechnology/GSK and other independent research groups. Further information on the efficacy of Xevudy against currently circulating virus variants, including the Delta and Omicron variants, is available in the updated product information.